Combination therapy with CTLA-4 inhibitors and PD-1/PD-L1 inhibitors have proved beneficial in advanced NSCLC, but they are limited by their serious side effects [2]. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.